NASDAQ:SLP Simulations Plus Q3 2026 Earnings Results & Report $18.50 0.00 (0.00%) As of 10/9/2026 Simulations Plus beat analyst expectations on both earnings and revenue in its Q3 2026 results, released July 9, 2026. The company reported EPS of $0.30 versus the $0.2325 consensus estimate, while revenue of $21.89 million topped the $20.90 million estimate by $0.99 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateJuly 9, 2026TimeBefore Market OpensConference Call4:00 PM ET Simulations Plus EPS ResultsActual EPS$0.30Consensus EPS $0.2325Beat/MissBeat by +$0.0675One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersSimulations Plus Revenue ResultsActual Revenue$21.89 millionExpected Revenue$20.90 millionBeat/MissBeat by +$990.00 thousandYoY Revenue GrowthN/AUpcoming EarningsSimulations Plus' Q4 2026 earnings is estimated for Thursday, October 29, 2026, based on past reporting schedules, with a conference call scheduled on Friday, October 23, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesSlide DeckPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Simulations Plus Q3 2026 Earnings FAQ Did Simulations Plus beat earnings estimates for Q3 2026? Simulations Plus (NASDAQ:SLP) reported earnings of $0.30 per share for Q3 2026, beating the consensus estimate of $0.2325. The report was announced on Thursday, July 9, 2026. What was Simulations Plus' revenue for Q3 2026? Simulations Plus reported revenue of $21.89 million for Q3 2026, against a consensus estimate of $20.90 million. When is Simulations Plus' next earnings date? Simulations Plus' next earnings date is estimated for Thursday, October 29, 2026. MarketBeat tracks confirmed and estimated earnings dates for Simulations Plus on the company's earnings history page. Simulations Plus Earnings HeadlinesSimulations Plus, Inc. Announces Funded Partnership With Global Pharmaceutical Company To Advance AI-Enabled QSP Model Development With TurinOctober 9, 2026 | marketscreener.comMSimulations Plus (NASDAQ:SLP) Given Neutral Rating at BTIG ResearchOctober 8, 2026 | americanbankingnews.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.October 13 at 1:00 AM | Banyan Hill Publishing (Ad)Altaris Completes Acquisition of Simulations PlusOctober 7, 2026 | finance.yahoo.comSimulations Plus, Inc.(NasdaqGS:SLP) dropped from Russell 2000 Growth BenchmarkOctober 6, 2026 | marketscreener.comMSimulations Plus Completes Altaris Acquisition and Goes PrivateOctober 6, 2026 | tipranks.comSee More Simulations Plus Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Simulations Plus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Simulations Plus and other key companies, straight to your email. Email Address About Simulations PlusSimulations Plus (NASDAQ:SLP) develops software and provides services that support pharmaceutical research, drug development and regulatory decision-making. Its technologies help scientists model how drug compounds behave in the body, assess formulation and delivery characteristics, and evaluate potential safety and efficacy outcomes. The company’s software portfolio includes GastroPlus, a platform for physiologically based pharmacokinetic and pharmacodynamic modeling; ADMET Predictor, which forecasts absorption, distribution, metabolism, excretion and toxicity properties; and DDDPlus, which simulates drug dissolution and dosage-form performance. Simulations Plus also offers tools for membrane permeability, medicinal chemistry and related drug-development applications. In addition to its software products, Simulations Plus provides consulting and contract research services involving pharmacometrics, pharmacokinetics, pharmacodynamics, clinical trial simulation and model-informed drug development. Founded in 1996, the company is headquartered in Lancaster, California, and serves pharmaceutical and biotechnology companies, regulatory agencies, academic institutions and other organizations worldwide.View Simulations Plus ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Delta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season NearsMarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
